
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated Jun 05, 2023, titled "Dr. Reddy s successfully completes Phase I study (IV route) of DRL_TC, a proposed biosimilar of tocilizumab".
Filed with NSE ·
Watch Dr. Reddy's Laboratories' latest callDr. Reddy's Laboratories (NSE:DRREDDY) Q1 2027 Earnings Call · Replay · Jul 22Read the transcript of Dr. Reddy's Laboratories (NSE:DRREDDY) Q1 2027 Earnings Call
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated Jun 05, 2023, titled "Dr. Reddy s successfully completes Phase I study (IV route) of DRL_TC, a proposed biosimilar of tocilizumab".
6ix hasn’t read this filing yet.
Dr. Reddy's Laboratories Ltd. on 6ix
Follow Dr. Reddy's Laboratories into a list and get an email when it puts out news.
Follow Dr. Reddy's Laboratories